Building on the success of the new Isotope Production System (IPS) installed in Unit 7 reactor, Bruce Power and Isogen (a partnership between Kinectrics and Framatome), are examining the feasibility of producing yttrium-90, used in the targeted liver cancer therapy.
The innovative IPS, designed and
manufactured by Isogen, was installed in Bruce Power’s Unit 7 during a recent
planned maintenance outage. The IPS is a first-of-its-kind solution to produce
short-lived medical isotopes in a commercial reactor. This collaboration and
the feasibility study between Bruce Power and Isogen is the next step in
determining future opportunities for this delivery capability.
Isogen and Bruce Power recently announced
the launch of a Global Expressions of Interest Process (EOI) for
radiopharmaceutical organizations interested in locating in Ontario for isotope
production. This process will run until mid-2023 and will help further cement
Ontario and Canada’s strong role as an isotope producer and supplier.
To
read more please visit:
Source: Bruce power